je.st
news
Tag: gsk
GSK buys HIV medicines for $1.4bn
2015-12-18 14:06:55| BBC News | Business | UK Edition
GlaxoSmithKline ends a frenetic week for the pharmaceutical sector with a $1.4bn takeover of HIV drug development assets from Bristol-Myers Squibb.
GSK to buy HIV drugs from Bristol-Myers Squibb for initial $350 million
2015-12-18 11:02:16| Biotech - Topix.net
It used to dominate the market but ViiV's 2014 sales of 1.5 billion pounds were less than a quarter of the HIV revenue generated by market leader Gilead Sciences ViiV will pay an initial $317 million to buy late-stage HIV drug candidates from Bristol-Myers, including a phase III development treatment fostemsavir, plus $33 million for its preclinical assets. HIV is often treated by mixing at least three medicines together because of the ability of the virus that causes AIDS to mutate and become drug-resistant.
Tags: buy
million
initial
drugs
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
2015-11-03 12:58:00| Merck.com - Product News
Dateline City: LONDON & KENILWORTH, N.J. Phase I first-in-human study to evaluate GSKs OX40 agonist GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSKs investigational immunotherapy GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. Language: English Contact: MerckMedia Relations:Pamela Eisele, +1 267-305-3558orAn Phan, +1 908-255-6325orInvestor Relations:Justin Holko, +1 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
potential
treatment
combination
GSK Heart Drug Flops In Study, Shingles Vaccine On Track
2015-10-28 08:39:04| Biotech - Topix.net
An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines. Losmapimod was being assessed as a treatment to reduce the risk of further cardiovascular problems after heart attacks, but it failed to show the hoped-for benefits and GSK said the result did not support investment in a larger second part of the study.
Unilever, Nestle, GSK and TUI to scale programmatic ads with dynamic creative
2015-10-16 11:47:51| Biotech - Topix.net
Unilever, Nestle, GlaxoSmithKline and TUI are looking to scale their programmatic media buying strategies with dynamic delivery of creative in an attempt to alleviate the problem of brands reaching the right audience, but with the wrong creative. Programmatic advertising technology is fundamentally about audience trading but in the rush to exploit its efficiencies the industry has yet to apply the potential benefits to produce more dynamic creative, according to speakers at this week's Ad:Tech conference.
Tags: creative
ads
scale
dynamic
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »